-
公开(公告)号：US07741019B2
公开(公告)日：2010-06-22
申请号：US10415222
申请日：2001-11-01
Applicant: Eleftherios P. Diamandis , Liu-Ying Luo
Inventor： Eleftherios P. Diamandis , Liu-Ying Luo
IPC: C12Q1/00 , G01N33/574
CPC classification number: G01N33/57449 , G01N2333/96455
Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.
Abstract translation: 一种通过检测来自受试者的样品中的hK10，优选血清样品或肿瘤组织提取物来诊断，预后和监测受试者的卵巢癌的方法。 可以使用检测或结合hK10的试剂优选hK10，优选与hK10或其一部分特异性反应的抗体。 还使用与hK10结合的试剂描述与hK10相关的肿瘤的成像方法，所述试剂具有用于成像肿瘤的标记。
-
公开(公告)号：US20120288873A1
公开(公告)日：2012-11-15
申请号：US13467661
申请日：2012-05-09
Applicant: Eleftherios P. Diamandis , Chan-Kyung Jane Cho , Eduardo Martinez Morillo
IPC: G01N33/566 , G01N21/82 , G01N21/64 , G01N27/62 , G01N33/573
CPC classification number: G01N33/689 , C12Q1/37 , C12Q1/44 , G01N33/6893 , G01N2333/4725 , G01N2800/385 , G01N2800/387 , G01N2800/50
Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.
Abstract translation: 该公开内容包括用于筛查胎儿唐氏综合征和/或21三体风险的测定和方法。 测定和方法包括确定选自粘蛋白13（MUC13），胆汁盐活化脂肪酶（CEL），二肽基肽酶4（DPP4），羧肽酶A1（CPA1），淀粉样蛋白前体蛋白（APP）和至少一种生物标志物的水平 来自怀孕受试者的测试生物样品中的腱生蛋白-C（Tasc-C）多肽，其中MUC13，CEL，DPP4和/或CPA1多肽的水平降低和/或增加的APP和/或TNC-C多肽水平 在测试生物样品中与相应的参考生物标志物多肽水平相比，表明唐氏综合征的风险增加或胎儿的21三体风险。 本公开还包括用于进行本文公开的方法的测定，组合物，免疫测定和试剂盒。
-
公开(公告)号：US5688658A
公开(公告)日：1997-11-18
申请号：US532808
申请日：1996-01-05
Applicant: Eleftherios P. Diamandis
Inventor： Eleftherios P. Diamandis
IPC: G01N33/50 , C12Q1/42 , C12Q1/68 , G01N33/543 , G01N33/574 , G01N33/58 , G01N33/48 , G01N33/53
CPC classification number: G01N33/57488 , C12Q1/6886 , G01N33/57415 , G01N33/582 , C12Q2600/106 , C12Q2600/112 , Y10S436/813
Abstract: This invention relates to the detection of prostate-specific antigen (PSA) in female breast tumor extract as a prognostic or predictive indicator for breast carcinoma. The presence of prostate-specific antigen in breast tumors is associated with earlier disease stage, younger women and better survival. PSA is associated with tumors which have estrogen and/or progesteron receptors.
Abstract translation: PCT No.PCT / CA94 / 00267 Sec。 371日期1996年1月5日 102（e）日期1996年1月5日PCT 1994年5月13日PCT公布。 第WO94 / 27152号公报 日期1994年11月24日本发明涉及女性乳腺肿瘤提取物中前列腺特异性抗原（PSA）检测作为乳腺癌的预后或预测指标。 乳腺肿瘤中前列腺特异性抗原的存在与早期疾病阶段，年轻女性和更好的生存相关。 PSA与具有雌激素和/或孕激素受体的肿瘤相关。
-
公开(公告)号：US20110256560A1
公开(公告)日：2011-10-20
申请号：US13125272
申请日：2009-10-20
Applicant: Eleftherios P. Diamandis , Cynthia Kuk
Inventor： Eleftherios P. Diamandis , Cynthia Kuk
IPC: G01N33/566
CPC classification number: G01N33/57449 , G01N33/57488 , G01N33/6842 , G01N2800/50 , G01N2800/52 , G01N2800/54
Abstract: Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.
Abstract translation: 本发明提供了筛选，诊断或检测受试者的卵巢癌的方法，其包括（a）确定来自受试者的测试样品中mdogen-2的水平，和（b）比较测试样品中mdogen-2的水平 与对照相比，检测样品中mdogen-2水平与对照相比增加的对照表明受试者的卵巢癌。
-
公开(公告)号：US07022497B1
公开(公告)日：2006-04-04
申请号：US09936271
申请日：2000-03-09
Applicant: George M. Yousef , Eleftherios P. Diamandis
Inventor： George M. Yousef , Eleftherios P. Diamandis
IPC: C12N15/00
CPC classification number: C07K14/705 , C12N9/6445
Abstract: The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.
Abstract translation: 本发明涉及由核酸分子编码的核酸分子，激肽释放酶样蛋白; 并使用蛋白质和核酸分子。
-
Patent Agency Ranking6.发明授权Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen 失效使用针对前列腺特异性抗原的药物进行非前列腺内分泌癌的定位和治疗
公开(公告)号：US6068830A
公开(公告)日：2000-05-30
申请号：US569206
申请日：1996-04-11
Applicant: Eleftherios P. Diamandis , Russell Redshaw
Inventor： Eleftherios P. Diamandis , Russell Redshaw
CPC classification number: A61K49/16 , A61K51/08 , A61K51/1051
Abstract: It was discovered that prostate-specific antigen is produced by non-prostatic endocrine cancers. It was further discovered that non-prostatic endocrine cancers with steroid receptors can be stimulated with steroids to cause them to produce PSA either initially or at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by labelled biological binding units which bind to prostate-specific antigen in an imaging procedure, such as, radioimaging or magnetic resonance imaging. Further, the PSA-binding units may be constructed to deliver a toxic agent, such as a radioisotope, toxin or a drug to provide endocrine cancer therapy. Another aspect of the invention is passive immunotherapy against endocrine cancers by treatment with PSA-binding units.
Abstract translation: PCT No.PCT / CA94 / 00392 Sec。 371日期：1996年4月11日 102（e）日期1996年4月11日PCT 1994年7月14日PCT公布。 出版物WO95 / 02424 日期1995年1月26日发现前列腺特异性抗原由非前列腺内分泌癌产生。 进一步发现，具有类固醇受体的非前列腺内分泌癌可以用类固醇刺激以使其最初或以更高的水平产生PSA。 本发明涉及通过在成像过程（例如放射成像或磁共振成像）中结合前列腺特异性抗原的标记的生物结合单位对非前列腺内分泌癌的成像。 此外，可以构建PSA结合单元以输送毒性剂，例如放射性同位素，毒素或药物以提供内分泌癌症治疗。 本发明的另一方面是通过用PSA-结合单元处理而对内分泌癌的被动免疫治疗。
-
公开(公告)号：US08574860B2
公开(公告)日：2013-11-05
申请号：US13467661
申请日：2012-05-09
Applicant: Eleftherios P. Diamandis , Chan-Kyung Jane Cho , Eduardo Martinez Morillo
IPC: G01N33/573 , A61K35/50 , A61K35/14 , A61K35/413 , A61K38/00 , A61P25/00
CPC classification number: G01N33/689 , C12Q1/37 , C12Q1/44 , G01N33/6893 , G01N2333/4725 , G01N2800/385 , G01N2800/387 , G01N2800/50
Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.
Abstract translation: 该公开内容包括用于筛查胎儿唐氏综合征和/或21三体风险的测定和方法。 测定和方法包括确定选自粘蛋白13（MUC13），胆汁盐活化脂肪酶（CEL），二肽基肽酶4（DPP4），羧肽酶A1（CPA1），淀粉样蛋白前体蛋白（APP）和至少一种生物标志物的水平 来自怀孕受试者的测试生物样品中的腱生蛋白-C（Tasc-C）多肽，其中MUC13，CEL，DPP4和/或CPA1多肽的水平降低和/或增加的APP和/或TNC-C多肽水平 在测试生物样品中与相应的参考生物标志物多肽水平相比，表明唐氏综合征的风险增加或胎儿的21三体风险。 本公开还包括用于进行本文公开的方法的测定，组合物，免疫测定和试剂盒。
-
公开(公告)号：US20130210666A1
公开(公告)日：2013-08-15
申请号：US13814959
申请日：2011-08-16
Applicant: Keith Jarvi , Eleftherios P. Diamandis , Andrei Drabovich
Inventor： Keith Jarvi , Eleftherios P. Diamandis , Andrei Drabovich
CPC classification number: G01N33/6893 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/68 , G01N33/689 , G01N2333/705 , G01N2333/78 , G01N2800/34 , G01N2800/342 , G01N2800/367
Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.
Abstract translation: 描述了用于检测受试者中泌尿生殖器官状态或泌尿生殖状态的方法，包括测量来自受试者的样品中的编码标志物的泌尿生殖标志物或多核苷酸。 本发明还提供泌尿生殖条件的定位或成像方法，以及用于实施本发明方法的试剂盒。 本发明还考虑了使用泌尿生殖标志物，编码标记物的多核苷酸和/或标记物的结合剂的泌尿生殖条件的治疗应用。
-
公开(公告)号：US07199229B2
公开(公告)日：2007-04-03
申请号：US10344394
申请日：2001-08-10
Applicant: George M. Yousef , Eleftherios P. Diamandis
Inventor： George M. Yousef , Eleftherios P. Diamandis
CPC classification number: C12N9/6445 , A61K38/00 , A61K39/00 , C07K16/40 , C12Y304/21034 , G01N33/57434
Abstract: The present invention relates to nucleic acid molecules, encoding kallikrein 15, a novel member of the kallikrein family. Also provided herein are vectors and host cells comprising the nucleic acid molecules, and methods for producing kallikrein 15 proteins.
Abstract translation: 本发明涉及编码激肽释放酶15的核酸分子，激肽释放酶家族的新成员。 本文还提供了包含核酸分子的载体和宿主细胞，以及产生激肽释放酶15蛋白的方法。
-
10.发明授权Detection of prostate-specific antigen in amniotic fluid, maternal serum and breast milk 失效检测羊水，母体血清和母乳中前列腺特异性抗原
公开(公告)号：US5679534A
公开(公告)日：1997-10-21
申请号：US509898
申请日：1995-08-01
Applicant: Eleftherios P. Diamandis
Inventor： Eleftherios P. Diamandis
IPC: C07K16/40 , G01N33/573 , G01N33/574 , G01N33/577
CPC classification number: G01N33/573 , C07K16/40 , G01N33/57434
Abstract: A method for the evaluation of the condition of a fetus by quantitative measurement of prostate specific antigen (PSA) is provided. In the method, a sample of amniotic fluid or maternal serum is obtained at a gestational week and the sample is assayed for the amount of PSA present. The amount of PSA in the sample is compared with the PSA mean for the given gestational week and evaluated for the risk of a phenotypic and/or genotypic disorder.
Abstract translation: 提供了通过前列腺特异性抗原（PSA）的定量测量来评估胎儿状况的方法。 在该方法中，在孕周获得羊水或母体血清样品，并测定样品中存在的PSA的量。 将样品中的PSA量与给定孕周的PSA平均值进行比较，并评估表型和/或基因型疾病的风险。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.023 seconds)
